Aventis Pharma SARL

The new laboratory will feature advanced genomics technology to support medical research by clinical labs and healthcare institutions, along with the agricultural sector, improving precision diagnoses and treatments The MGI Brazil Customer Experience Center. (Credit: PRNewswire/ MGI) Chinese biotechnology company MGI Tech has launched its Customer Experience Center (CEC) in Brazil, to help advance the development of genomics technologies in Latin America. The new 270m2 CEC facility, located in Brooklin Paulista, in São Paulo, Brazil, is designed to provide clinical laboratories, universities, and hospitals with advanced technology. The Brazilian facility will comprise the Next Generation Sequencing (NGS) lab, automation lab, BIT lab and engineering lab. It will feature the high throughput sequencer DNBSEQ-T7, the high-speed sequencer DNBSEQ-G99, and flexible DNBSEQ-G400, and the portable sequencer DNBSEQ-E25. The automation lab at the new CEC facility provides advanced technology, with sample preparation systems, MGISP-100 and MGISP-960. It also features high and low-throughput automated nucleic acid extractors, MGISP-384 and MGISP-NE32, and automated sample transfer processing systems MGISTP-7000. Furthermore, it also includes bioinformatics products such as ZTRON Pro data processing and storage platform, and MegaBOLT bioinformatics analysis accelerator series. MGI LATAM senior commercial director and MGI Brazil general manager Carlos Carpio said: “As the demand for next-generation sequencing tests in cancer diagnostics and genetic screening increases, hospitals, clinics, laboratories and universities need to rely on supporting laboratories to improve their capabilities with affordable solutions faster sample processing speed and high data quality. “Our Customer Experience Center will be able to contribute significantly to the scientific development of the region by reducing sequencing costs, expanding clinical applications and, therefore, making precision diagnoses and treatments more accessible to the population.” MGI aims to provide clinical and research laboratories, hospitals, and universities with a facility to enhance their learning and experience with genetic sequencing technology. The company is also focused on supporting the understanding of precision medicine, oncology, and metagenomics, among other segments. MGI has been operating in Latin America since 2019 and has partnered with Fiocruz in Brazil, Biogenar in Argentina, Gencell in Colombia, Genos in Mexico and TCL Group in Chile. The new CEC facility will play an important role as the MGI Hub in Brazil and allow for the expansion of its operations across Latin America, said the company. MGI said that the technology also supports the genomic sequencing project in Brazil. The project aims to sequence the complete genomes of patients with rare diseases and hereditary cancers, to identify genetic markers for early diagnosis of inherited diseases. MGI’s genomic project coordinator João Bosco de Oliveira Filho said: “I had a wonderful experience working with MGI’s team. The technology is solid, the data quality is outstanding and the support is available when needed.” “Researchers and diagnostic laboratories need to stay up-to-date on available technologies to advance their studies and tests; therefore, it is very important to have a local support laboratory and service personnel.”

The laboratory has state-of-the-art technology to support medical research of clinical labs and healthcare institutions, improving precision diagnoses and treatments. The agricultural sector can also benefit. SAO PAULO, April 19, 2024 /PRNewswire/ -- Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil. Commitment to Brazil healthcare Continue Reading The MGI Brazil Customer Experience Center The MGI Brazil Customer Experience Center Automation products in the lab The goal is to provide a facility for clinical and research laboratories, hospitals, and universities to enhance learning and experience with genetic sequencing technology, applied in precision medicine, oncology, agrigenomics (application of the genome in agriculture) and metagenomics (collection of genomes of environmental microbial communities), among other segments. "Genomic research has grown exponentially in the region. As the demand for next generation sequencing tests in cancer diagnostics and genetic screening increases, hospitals, clinics, laboratories and universities need to rely on supporting laboratories to improve their capabilities with affordable solutions faster sample processing speed and high data quality", says Carlos Carpio, Senior Commercial Director of MGI LATAM and General Manager of MGI Brazil. "Our Customer Experience Center will be able to contribute significantly to the scientific development of the region by reducing sequencing costs, expanding clinical applications and, therefore, making precision diagnoses and treatments more accessible to the population", he adds. The lab will also play a role as MGI Hub in Brazil, allowing the expansion of operations across Latin America. It demonstrates MGI's enduring dedication to broadening global genomics accessibility in this region. MGI has been operating in Latin Americas since 2019 and has already partnered with many clients, such as Fundação Oswaldo Cruz (Fiocruz) in Brazil, Biogenar in Argentina, Gencell in Colombia, Genos in Mexico and TCL Group in Chile. In Brazil, MGI's technology also supports the largest Brazilian genomic sequencing project, which aims to sequence the complete genomes of thousands of patients with rare diseases and hereditary cancers, searching for genetic markers to track inherited diseases for early diagnosis. Coordinator of the genomic project, Dr. João Bosco de Oliveira Filho highlights MGI's technology: "I had a wonderful experience working with MGI's team. The technology is solid, the data quality is outstanding and the support is available when needed", he also welcomes the importance of the launch of the CEC: "Researchers and diagnostic laboratories need to stay up-to-date on available technologies to advance their studies and tests; therefore, it is very important to have a local support laboratory and service personnel". State-of-the-art technology provided in the Lab MGI operates in 100 countries and has other 9 Customer Experience Centers around the world. The Brazilian center, located in Brooklin Paulista, in São Paulo, will provide a place for clinical laboratories, universities, and hospitals to engage in demonstrations, enhancing their education and experience with the company's technology. Highly skilled professionals will lead certified training sessions, demonstrations, evaluations and local new application support. CEC, with 270 m2, comprises four distinct areas: NGS (Next Generation Sequencing) lab, automation lab, BIT lab and engineering lab. MGI's sequencing experience features the high throughput sequencer DNBSEQ-T7, high speed sequencer DNBSEQ-G99, the robust and flexible DNBSEQ-G400, and portable and easy-to-use sequencer DNBSEQ-E25*. At the automation lab, the company offers access to cutting-edge technology, with sample preparation system MGISP-100 and MGISP-960, high and low throughput automated nucleic acid extractor MGISP-384 and MGISP-NE32, and automated sample transfer processing system MGISTP-7000. There are also bioinformatics products such as ZTRON Pro, a data processing platform and storage, and MegaBOLT, a bioinformatics analysis accelerator series. Researchers and other professionals will be able to experience the range of end-to-end MGI solutions in the CEC São Paulo, as it is fully equipped to conduct genomics laboratory protocols. CEC São Paulo is located at Avenida das Nações Unidas, 11633 – 15 floor – Brooklyn – São Paulo. Further information: [email protected]. *Certain sequencers can be used for research purposes only and not for use in any diagnostic procedures. Please consult MGI's local contactor for details. SOURCE MGI

Through the new partnerships, MGI will supply latest sequencing and lab automation platforms to its local partners in Latin America, reaffirming its dedication to advancing genomics and enhancing human health in the region MGI’s high-throughput sequencing set uses DNBSEQ technology. (Credit: RPSkokie/Wikipedia) Chinese biotechnology firm MGI Tech has teamed up with Mexican genomics company Genos Médica and Chilean laboratory equipment supplier TCL Group to expand its advanced sequencing and lab automation platforms offering to local partners in Latin America. According to MGI, the healthcare landscape in Latin America has been changing rapidly, with increasing demand for high-throughput sequencing technologies and testing. Genetic testing enables scientific researchers to identify the sequence of DNA or RNA to study genetic variation related to diseases and respond with customised treatment. The Chinese biotechnology company partnered with Genos Médica to provide local laboratories and institutes with advanced life science tools and enhance their genetic testing capabilities. Established in 2011, the Mexican company provides complete management of hereditary diseases through its consultation services and specialised laboratory. The collaboration between Genos Médica and MGI aims to establish a complete workflow with faster turnaround times. The partnership includes MGI’s DNBSEQ-T7 Ultra-high-throughput Genetic Sequencer, DNBSEQ-G50 Benchtop Genetic Sequencer, MGISP-960 High-Throughput Automated Sample Preparation System, and data platform appliance ZTRON. MGI LATAM senior commercial director and MGI Brazil general manager Carlos Carpio said: “Over the last four years, we have witnessed rapid growth in the high-throughput sequencing market in Latin America and are confident in its upward trajectory. “We are thrilled to partner with Genos Médica and TCL Group to increase our presence further within the vibrant biotech ecosystem in LATAM and look forward to unlocking new opportunities for advancing local healthcare.” Genos Médica genetic scientist Ocelotl Azotla Vilchis said: “Due to the genetic richness of people in Latin America and rising demands for genetic testing, we have been in search of advanced yet affordable technologies to develop a deeper understanding of our genetic variations and improve patient outcomes. “Sharing the same belief and goal, we are pleased to collaborate with MGI and leverage their accessible and innovative sequencing solutions to address demands and challenges in LATAM’s growing genomics market.” TCL Group has 28 years of experience providing diagnostics and biotech solutions in Chile. The laboratory equipment supplier has partnered with MGI to import five units of the DNBSEQ-G400 benchtop sequencer and three of the ultra-high speed DNBSEQ-G99 sequencer. In addition, TCL Group has acquired MGISP-960 and MGISP-100 automated sample preparation systems to address emerging market needs. TCL Group scientific advisor Carlos Meyer-Regueiro said: “Having built a great reputation in Chile for our excellent service to clients with high-quality life sciences equipment and supplies, we have seen the genomics market evolve and demands for more comprehensive, flexible and efficient instruments increase. “We are thrilled to work with MGI and are confident in the comprehensive capabilities of their technologies and instruments in satisfying a variety of genomics needs, with an outstanding technical support team.” Earlier this year, MGI announced a partnership with Gencell in Colombia, integrating its advanced DNBSEQ technology with Gencell’s expertise and local market presence. Furthermore, the Chinese medical device maker is planning to open a new Customer Experience Centre (CEC) in São Paulo, Brazil, by Q1 2024 to support the customers and partners in Latin America.